CellCentric, a Cambridge, UK-based clinical-stage biotechnology company, raised $120M in Series C funding.
The round was led by RA Capital Management and new investor Forbion, with participation from Avego Bioscience Capital, as well as BrightEdge, the American Cancer Society’s venture capital and impact investment arm.
Led by CEO Will West, CellCentric is a clinical stage biotech company advancing Inobrodib, which is a new treatment for people with cancer, and multiple myeloma in particular. Its small molecule drug targets p300/CBP, lowering the expression of key cancer drivers, MYC and IRF4. Delivered as an oral capsule, it can be used at home without the need for intensive monitoring. As it has a good safety profile for a drug in this setting, it may be used by those who are unable to access or tolerate other types of treatment.
The company intends to use the funds to:
- Accelerate the Phase II/III study in heavily pretreated multiple myeloma patients, with the potential to support an accelerated approval.
- Support development activities for a Phase III program, to start mid-2026.
- Accelerate trials starting Q2 2025, including the combination of inobrodib with bi-specific antibodies, as well as inobrodib in a maintenance setting.
FinSMEs
19/05/2025